Clinical Genetics Branch (CGB) investigators conduct clinical, genetic, and epidemiologic studies of individuals at high genetic risk of cancer in order to improve our understanding of cancer etiology and to advance clinical care.
CGB's research mission is to conduct multidisciplinary research to advance our understanding of the molecular pathogenesis of cancer and to translate this knowledge into effective clinical applications for cancer-prone individuals and families. Learn about specific CGB research areas.
CGB fellows work with researchers engaged in conducting clinical research studies targeting high-risk families, in pursuing astute clinical observations of unusual cancer occurrences that might provide new clues to cancer etiology, and in applying epidemiologic methods to the study of high-risk individuals. Meet the current CGB fellows and learn about research training opportunities in CGB.
Dr. Gadalla joined CGB in 2008 to investigate the role of genetic factors in cancer etiology and to explore factors that may modify disease risk among individuals at high risk of developing cancer. She was recently appointed as an NIH Earl Stadtman Investigator. Read more about Dr. Gadalla's appointment.
Gadalla SM, Wang T, Haagenson M, et al. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia. JAMA 2015 Feb;313:594-602
Schiffman M, Burk RD, Boyle S, et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.J Clin Microbiol 2015 Jan;53:52-59
Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.J Natl Cancer Inst 2014 Jul;18;106
Kocak H, Ballew BJ, Bisht K, et al. Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1.Genes Dev 2014 Oct;28:2090-2102
Sherman ME, Piedmonte M, Mai PL, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 2014 Oct;32:3275-3283